ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: TH-PO270

A Novel Electronic Surveillance Program to Track Bloodstream Infections in Haemodialysis Patients (SPoT-BSI)

Session Information

Category: Dialysis

  • 703 Dialysis: Vascular Access


  • Lazarus, Ben, Monash University, Clayton, Victoria, Australia
  • Polkinghorne, Kevan, Monash University, Clayton, Victoria, Australia
  • Duong, Alex, Monash Health, Clayton, Victoria, Australia
  • Seneviratne, Mechelle Karen, Monash Health, Clayton, Victoria, Australia
  • Rogers, Benjamin A., Monash University, Clayton, Victoria, Australia

Accurate surveillance of ARBSI among haemodialysis patients is important for delivering high quality healthcare. Existing surveillance systems require substantial manual data collection, which may be prone to error and resource intensive. A system that uses automated analysis of routinely collected data may be more accurate and less burdensome. We aimed to measure the incidence of haemodialysis access-related bloodstream infection (ARBSI) using routinely collected electronic health data.


We linked routinely collected data from the electronic medical record (EMR) between 1st January 2021 and 31st December 2021 to laboratory blood culture data identifying haemodialysis (HD) treatments, access modality, and positive blood cultures among adult HD patients. We calculated exposure time by access type. For patients with a positive blood culture within 30 days of HD treatment the source of infection was assessed by manual review of the EMR. Definitions for HD catheter-related BSI (HDCRBSI) and arteriovenous ARBSI (AV-ARBSI) followed those used by the Center for Disease Control National Healthcare Surveillance Network.


In total we identified 648 patients who received haemodialysis, 21,189 catheter days and 127,873 arteriovenous access days of exposure, and 51 cases of positive blood cultures, of which 10 were HDCRBSI, 4 were AV-ARBSI, 11 were contaminants, and 26 were from alternative sources. The incidence rate of HDCRBSI (0.47 events per 1000 catheter days, 95% CI, 0.18-0.76) was 15.1 times higher (95% CI 4.35 – 65.90) than for AV access-related BSI (0.03 events per 1000 access days, 95% CI, 0.0006-0.06)


Routinely collected electronic health data can be used to enhance the surveillance of access related bloodstream infections, although clinical assessment of positive cultures is still required.


  • Government Support – Non-U.S.